SCHEMBL447573

SCHEMBL447573

COC(=O)CC(=O)c1ccccc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.70
CTSD P07339 1/20 0.61
IDO1 P14902 1/20 0.60
TDO2 P48775 1/20 0.60
HDAC8 Q9BY41 1/20 0.56
HDAC1 Q13547 1/20 0.56
ALDH1A1 P00352 1/20 0.54
HTT P42858 1/20 0.54
KMT2A Q03164 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
LMNA P02545 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
STAT3 P40763 1/20 0.53
HPGD P15428 2/20 0.53
TP53 P04637 1/20 0.53
GLA P06280 1/20 0.53
CTNNB1 P35222 2/20 0.53
WNT3A P56704 2/20 0.53
RAB9A P51151 2/20 0.51
KCNK3 O14649 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29987209 0.90 NPC1 (0.83) NPC1CTSDIDO1TDO2HDAC8
SCHEMBL21128714 0.90 NPC1 (0.83) NPC1CTSDIDO1TDO2HDAC8
SCHEMBL30218361 0.86 NPC1 (0.62) NPC1CTSDIDO1TDO2HDAC8
SCHEMBL954173 0.86 NPC1 (0.62) NPC1CTSDIDO1TDO2HDAC8
SCHEMBL31686110 0.86 CTNNB1 (0.66) NPC1CTSDIDO1TDO2HDAC8
SCHEMBL26644901 0.86 CTNNB1 (0.66) NPC1CTSDIDO1TDO2HDAC8
SCHEMBL2723234 0.85 NPC1 (0.75) NPC1CTSDIDO1TDO2HDAC8
SCHEMBL31337028 0.85 NPC1 (0.70) NPC1CTSDIDO1TDO2HDAC8
SCHEMBL2222069 0.85 NPC1 (0.70) NPC1CTSDIDO1TDO2HDAC8
SCHEMBL18787732 0.85 NPC1 (0.60) NPC1CTSDIDO1TDO2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10953012-B2 Heterocyclic compounds for the inhibition of pask BIOENERGENIX LLC (US) 2021-03-23 US disclosed
US-10953012-B2 Heterocyclic compounds for the inhibition of pask BIOENERGENIX LLC (US) 2021-03-23 US disclosed
WO-2012149157-A2 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-11-01 WO disclosed
WO-2012149157-A2 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-11-01 WO disclosed
US-20120277224-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-11-01 US disclosed
US-20120277224-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-11-01 US disclosed
US-20120277224-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-11-01 US disclosed
EP-2221296-B1 FUSED INDANE COMPOUND ASTELLAS PHARMA INC (JP) 2012-09-05 EP disclosed
US-8211907-B2 Fused indane compound ASTELLAS PHARMA INC. (JP) 2012-07-03 US disclosed
US-20120065063-A1 3-Aryl-4-(2,6-dimethylbenzylidene)isoxazol-5(4H)-ones as Fungicides BAYER CROPSCIENCE AG (DE) 2012-03-15 US disclosed
US-20030092740-A1 Inhibitors of factor Xa with a neutral P1 specificity group GALEMMO ROBERT A (US) 2003-05-15 US disclosed
US-6403620-B1 ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-06-11 US disclosed
EP-0991625-A2 INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 2000-04-12 EP disclosed
US-5998424-A ANTICOAGULANTS DUPONT PHARMACEUTICALS COMPANY (US) 1999-12-07 US disclosed
WO-1998057937-A2 INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-12-23 WO disclosed
US-5354869-A Fluorescent dyes RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) 1994-10-11 US disclosed
US-4179294-A POLYMER MORDANT, ACIDIC PYRAZOLONE-CONTAINING OXONOL DYE, READILY DECOLORIZED BY IMMOBILIZATION FUJI PHOTO FILM CO., LTD. (JP) 1979-12-18 US disclosed
US-4026709-A Color photographic recording material CIBA-GEIGY AG (CH) 1977-05-31 US disclosed
US-3984432-A PHOSPHONIC ACID AND PHOSPHORIC ACID DERIVATIVES CIBA-GEIGY AG (CH) 1976-10-05 US disclosed
US-3950381-A Preparation of aroyl acidic esters BAYER AKTIENGESELLSCHAFT (DT) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277224-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK PASK, PDXK, PANK2 NPC1 3570/4885CTSD 941/4885IDO1 4379/4885
US-20030092740-A1 Inhibitors of factor Xa with a neutral P1 specificity group F12, F11, SERPINC1 NPC1 787/4885CTSD 2644/4885IDO1 2148/4885
US-10953012-B2 Heterocyclic compounds for the inhibition of pask PASK, PDXK, PANK2 NPC1 3570/4885CTSD 941/4885IDO1 4379/4885
US-20120065063-A1 3-Aryl-4-(2,6-dimethylbenzylidene)isoxazol-5(4H)-ones as Fungicides CYP4X1, CYP4Z1, HAAO NPC1 3725/4885CTSD 3262/4885IDO1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.